How Much Does Alprostadil (Caverject/MUSE) Cost in North Dakota in 2026?

Brand-Name Pricing at North Dakota Pharmacies

The average cash-pay price for brand-name Caverject (alprostadil for injection) at North Dakota retail pharmacies in 2026 sits around $600 per month. MUSE (alprostadil urethral suppository) lands in a similar range, though pricing varies by dose strength and quantity. North Dakota has roughly 130 retail pharmacies spread across urban centers like Fargo, Bismarck, Grand Forks, and Minot, plus dozens of smaller-town locations. Price variation between them can reach 15-25%.

The FDA originally approved alprostadil for intracavernosal injection (Caverject) in 1995 based on data showing efficacy in men with erectile dysfunction of diverse etiologies, including vascular, neurogenic, and psychogenic causes [1]. A key trial published in the New England Journal of Medicine by Linet and Ogrinc (1996) enrolled 296 men and demonstrated that 87% of intracavernosal alprostadil injections produced erections sufficient for intercourse, compared to 13% with placebo [2]. That efficacy profile remains relevant today because alprostadil is one of the few second-line options for men who do not respond to oral PDE5 inhibitors like sildenafil or tadalafil.

Pricing has climbed steadily since launch. The wholesale acquisition cost (WAC) set by Pfizer for Caverject has increased roughly 4-7% per year over the past decade, tracking with broader specialty drug inflation trends documented by the AARP Rx Price Watch reports. Patients paying out of pocket in Fargo or Bismarck should request price quotes from multiple pharmacies before filling a prescription.

North Dakota Medicaid and Alprostadil

North Dakota Medicaid does not cover alprostadil for erectile dysfunction. This aligns with a federal policy rooted in the Deficit Reduction Act of 2005, which prohibited state Medicaid programs from covering erectile dysfunction drugs. The restriction applies to both Caverject and MUSE regardless of the prescribing indication code when ED is the primary diagnosis.

There is one narrow exception worth knowing. If a prescriber documents that alprostadil is being used for a non-ED indication (such as peripheral vascular disease diagnosis or neonatal ductus arteriosus management in a hospital setting), the claim may process under different coverage rules. However, for the vast majority of adult men seeking alprostadil for erectile dysfunction in North Dakota, Medicaid is not a viable payment pathway.

North Dakota expanded Medicaid in 2014 under the Affordable Care Act, and the state contracts with managed care organizations to administer benefits. Even within those managed plans, ED medications remain carved out of formulary coverage per federal guidance from CMS [3]. Patients on Medicaid who need second-line ED therapy should discuss alternatives with their provider, including vacuum erection devices, which North Dakota Medicaid does cover as durable medical equipment.

Commercial Insurance Coverage in North Dakota

Private insurers in North Dakota handle alprostadil coverage inconsistently. Blue Cross Blue Shield of North Dakota, Sanford Health Plan, and Medica are the dominant commercial carriers in the state. Some plans include alprostadil on specialty tiers with prior authorization requirements, while others exclude ED medications entirely.

Prior authorization criteria, when coverage exists, typically require documentation that the patient has tried and failed at least one oral PDE5 inhibitor. According to American Urological Association (AUA) guidelines, intracavernosal alprostadil is recommended as second-line therapy after oral agents [4]. Insurers reference this stepped approach when setting coverage rules.

Patients with employer-sponsored plans should check their Summary of Benefits and Coverage (SBC) document for the specific drug exclusion list. Self-funded employer plans, common among larger North Dakota employers like Bobcat (Doosan) and Basin Electric, set their own formulary rules and may cover alprostadil even when fully-insured small group plans do not.

For men with Medicare Part D in North Dakota, the same federal ED drug exclusion applies. The Inflation Reduction Act's Part D redesign capped out-of-pocket spending at $2,000 per year starting in 2025, but that cap does not help with alprostadil because the drug is excluded from Part D formularies for ED [5].

Compounded Alprostadil in North Dakota

Compounded alprostadil is legal in North Dakota through licensed 503A compounding pharmacies. This is one of the most practical cost-reduction strategies available to North Dakota patients. A 503A pharmacy operates under a patient-specific prescription from a licensed prescriber, and North Dakota's Board of Pharmacy regulates these facilities under NDCC Chapter 43-15 and associated administrative rules.

Compounded alprostadil formulations often come as part of a "trimix" or "bimix" combination. Trimix typically contains alprostadil, papaverine, and phentolamine. Bimix omits one of the latter two agents. These combinations can reduce the required alprostadil dose per injection, which reduces side effects like penile pain, a complaint reported in 37% of patients in the Linet and Ogrinc trial [2].

The cost difference is substantial. Where brand Caverject runs $600/month, compounded alternatives from 503A pharmacies, including some that ship to North Dakota from out-of-state licensed facilities, can range from $50 to $150 per month depending on the formulation, concentration, and volume. Patients should confirm that any out-of-state compounding pharmacy holds a valid non-resident pharmacy license with the North Dakota Board of Pharmacy.

One caution: 503B outsourcing facilities, which compound without individual prescriptions for office use, operate under different FDA oversight per Section 503B of the Federal Food, Drug, and Cosmetic Act. A 2023 FDA inspection cycle found quality issues at several 503B facilities nationally [6]. Patients should ask their provider whether the compounding source is 503A (patient-specific) or 503B (office-use), as the regulatory and quality assurance frameworks differ.

Telehealth Access in North Dakota

North Dakota permits telehealth prescribing of alprostadil. The state's telehealth parity law (NDCC 26.1-36-09.15) requires insurers to cover telehealth-delivered services at the same rate as in-person visits when the service is clinically appropriate. For alprostadil, this means a prescriber licensed in North Dakota can evaluate a patient via video or audio-visual consultation, diagnose erectile dysfunction, and prescribe alprostadil without an in-person exam.

This matters in a state with North Dakota's geography. Over 40% of the state's population lives in rural areas, and the nearest urologist may be 100+ miles away. Telehealth platforms that operate in North Dakota can connect patients with prescribers who have experience with intracavernosal injection therapy and can provide the initial dosing titration guidance that alprostadil requires.

The first injection of alprostadil ideally occurs under medical supervision because dose titration is necessary and priapism (prolonged erection lasting >4 hours) is a medical emergency that occurs in approximately 1% of patients [2]. Some telehealth providers coordinate with local clinics for this supervised first dose while managing ongoing prescriptions remotely.

Dr. Arthur Burnett, a professor of urology at Johns Hopkins and contributor to the AUA erectile dysfunction guidelines, has noted: "Intracavernosal injection therapy remains the most effective non-surgical treatment for erectile dysfunction, with response rates exceeding 80% across all etiologies" [4]. That efficacy, combined with telehealth access, makes alprostadil a realistic option even for patients in rural North Dakota communities like Williston, Dickinson, or Devils Lake.

Manufacturer Savings Programs and Discount Cards

Pfizer offers a savings card for Caverject that can reduce copays for commercially insured patients. The card typically covers up to a set dollar amount per fill, with annual caps. Patients with government insurance (Medicaid, Medicare, Tricare, VA) are not eligible for manufacturer copay cards per federal anti-kickback statute requirements.

Generic alprostadil for injection is available from several manufacturers, and some offer their own savings programs. Generic pricing at North Dakota pharmacies tends to run 10-20% below brand Caverject, though the gap is narrower than patients typically expect for generic medications. The sterile injectable formulation and cold-chain storage requirements limit the cost savings that generic manufacturers can pass through.

GoodRx, RxSaver, and similar discount aggregator platforms show North Dakota prices for alprostadil ranging from roughly $400 to $650 depending on the pharmacy, dose, and quantity. These platforms negotiate rates with pharmacy benefit managers, and the prices they display are cash-pay discount rates, not insurance-adjudicated prices. Patients should compare the discount card price with their insurer's negotiated rate (if covered) and with compounded alternatives before deciding.

A few additional cost-reduction strategies specific to North Dakota:

The North Dakota Pharmaceutical Assistance Program does not currently include alprostadil on its covered drug list, but patients aged 65+ with limited income should check eligibility annually as the formulary updates. Patient assistance programs through NeedyMeds (needymeds.org) aggregate manufacturer programs and may identify options that a pharmacy search alone would miss.

Dosing, Storage, and Practical Cost Considerations

Alprostadil dosing is individualized, which directly affects monthly cost. Caverject is available in 10 mcg, 20 mcg, and 40 mcg single-use vials. Starting dose is typically 2.5 mcg for neurogenic ED or 10 mcg for vasculogenic ED, titrated upward in-office until an adequate response is achieved, per the FDA-approved prescribing information [7]. MUSE comes in 125 mcg, 250 mcg, 500 mcg, and 1 to 000 mcg suppositories.

A patient using alprostadil twice per week at 20 mcg per injection will go through roughly 8-10 doses per month. At brand-name pricing, this translates to approximately $60-75 per dose. The same frequency with compounded trimix from a 503A pharmacy might cost $5-15 per dose, a difference that adds up to thousands of dollars annually.

Storage requirements add a hidden cost layer. Caverject powder for reconstitution is stable at room temperature, but the reconstituted solution must be refrigerated and used within 24 hours. Caverject Impulse (the pre-filled dual-chamber system) has a longer post-reconstitution window. MUSE suppositories require refrigeration at 2-8°C. Patients without reliable refrigeration in remote areas of western North Dakota should factor this into their formulation choice.

A 2019 meta-analysis published in the Journal of Sexual Medicine examined alprostadil efficacy across 10 randomized controlled trials involving 2,049 patients and confirmed intracavernosal alprostadil response rates of 70-87% [8]. The analysis noted that penile pain, the most common side effect, decreased with continued use in most patients, from 37% at initiation to approximately 10-15% after 3 months of regular injections.

How North Dakota Compares to Neighboring States

North Dakota's alprostadil pricing sits close to the regional average for the upper Midwest. Montana and South Dakota show similar cash-pay prices in the $550-650 range. Minnesota tends to run slightly lower ($500-580) due to greater pharmacy competition in the Minneapolis-St. Paul metro. All four states permit 503A compounded alprostadil and telehealth prescribing.

The meaningful difference is Medicaid. No state in this region covers alprostadil for ED through Medicaid, so the federal exclusion creates a uniform barrier. Commercial insurance variation is the bigger differentiator, and that depends on the specific employer or plan rather than the state.

For North Dakota residents near the Minnesota border (Fargo-Moorhead area), it may be worth comparing pharmacy pricing across state lines. North Dakota does not impose a sales tax on prescription medications, which provides a small but real advantage over states that do tax prescriptions.